Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Net Income Loss of $31.11 million for the year ending 2025.
- PUMA BIOTECHNOLOGY, INC. showed an increase of +2.8% in Net Income Loss from 2024 to 2025.
- This data is from PUMA BIOTECHNOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), PUMA BIOTECHNOLOGY, INC.'s Net Income Loss has grown by 404.0%.
- Historical annual values: Fiscal year 2025: $31.11 million | Fiscal year 2024: $30.28 million | Fiscal year 2023: $21.59 million | Fiscal year 2022: $2.0 thousand | Fiscal year 2021: -$29.13 million | Fiscal year 2020: -$60.00 million | Fiscal year 2019: -$75.60 million | Fiscal year 2018: -$113.58 million | Fiscal year 2017: -$291.96 million | Fiscal year 2016: -$276.01 million | Fiscal year 2015: -$239.28 million | Fiscal year 2014: -$141.97 million | Fiscal year 2013: -$54.66 million | Fiscal year 2012: -$74.35 million | Fiscal year 2011: -$10.23 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: